Impact of Initiating Insulin Glargine Disposable Pen Versus Vial/Syringe on Real-World Glycemic Outcomes and Persistence Among Patients with Type 2 Diabetes Mellitus in a Large Managed Care Plan: A Claims Database Analysis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diabetes accounts for almost 15% of all direct healthcare expenditures. Managed care organizations try to reduce costs and improve patient outcomes. Increasing patient persistence with antidiabetes treatment could help achieve these goals. SUBJECTS AND METHODS: A retrospective study was conducted using the Optum Research Database (Optum, Eden Prairie, MN) to analyze clinical and economic outcomes associated with initiation of insulin glargine via a disposable pen (GLA-P) or vial and syringe (GLA-V) among adult, insulin-naive patients with type 2 diabetes mellitus (T2DM). Propensity-matched patient cohorts were assessed for persistence with insulin therapy, glycated hemoglobin (A1C), hypoglycemic events (based on diagnosis codes), and healthcare costs (total paid amount of adjudicated claims) after follow-up at 1 year. RESULTS: In 1,308 matched patients, persistence was significantly higher (P=0.011) and longer (P=0.001) with GLA-P. Follow-up A1C values were significantly lower (P=0.038), and decreases in A1C from baseline significantly larger (P=0.043), in GLA-P than in GLA-V. Significantly fewer hypoglycemic events (P=0.042) were experienced, and a lower rate of diabetes-related inpatient admissions (P=0.008) was reported in GLA-P than GLA-V. Despite higher study drug costs with GLA-P than GLA-V, all-cause and diabetes-related healthcare costs were similar. CONCLUSIONS: In insulin-naive patients with T2DM, initiation of insulin glargine using the disposable pen rather than the vial and syringe is associated with higher persistence, better A1C control, and lower rates of hypoglycemia. The higher study drug costs associated with pen use do not increase total all-cause or diabetes-related healthcare costs. This may help treatment selection for patients with T2DM in a managed care setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
Balkrishnan, R., Rajagopalan, R., Camacho, F. T., Huston, S. A., Murray, F. T., & Anderson, R. T. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80347-8 · Cited by 350
Cited by
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784
Pozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633721 · Cited by 63
“A subanalysis was performed using the studies with similar definitions of discontinuation threshold.(14,15,18,26) The favorable tendency for”
MethodSteenkamp, D., Eby, E. L., Gulati, N., & Liao, B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821997923 · Cited by 33
Metadata
- Authors
- Xie, L., Zhou, S., Pinsky, B. W., Buysman, E. K., & Baser, O.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2014-09
- Volume
- 16
- Issue
- 9
- Pages
- 567-575
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1866087940
- Cited by
- 29
- References
- 2
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Initiating Insulin Glargine Disposable Pen Versus Vial/Syringe on Real-World Glycemic Outcomes and Persistence Among Patients with Type 2 Diabetes Mellitus in a Large Managed Care Plan: A Claims Database Analysis. https://app.cochat.ai/papers/10.1089/dia.2013.0312
- The paper
- Xie, L., Zhou, S., Pinsky, B. W., Buysman, E. K., & Baser, O. (2014). Impact of Initiating Insulin Glargine Disposable Pen Versus Vial/Syringe on Real-World Glycemic Outcomes and Persistence Among Patients with Type 2 Diabetes Mellitus in a Large Managed Care Plan: A Claims Database Analysis. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2013.0312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.